Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.44 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516401 | 0.79 | PARP1 (0.48) | PIM1PDGFRBFGFR1KDRAURKA | |
| SCHEMBL4493806 | 0.78 | ACHE (0.43) | — | |
| SCHEMBL4496187 | 0.77 | PARP1 (0.49) | PARP1 | |
| SCHEMBL7954749 | 0.77 | PKN1 (0.49) | CYP3A4PKN1PKN2ADORA3MGAM | |
| SCHEMBL4499273 | 0.76 | RIPK1 (0.61) | PIM1PKN1PKN2AURKARPS6KB1 | |
| SCHEMBL4490880 | 0.75 | PDGFRB (0.58) | PIM1PDGFRBFGFR1KDRCHEK1 | |
| SCHEMBL7966265 | 0.75 | KAT2B (0.52) | PIM1PKN1PKN2ADORA3MGAM | |
| SCHEMBL8601355 | 0.74 | PKN1 (0.55) | CYP3A4PKN1PKN2ADORA3MGAM | |
| SCHEMBL7477180 | 0.74 | RIPK1 (0.46) | PKN1PKN2ADORA3MGAMGAA | |
| SCHEMBL7016736 | 0.74 | PKN1 (0.46) | PKN1PKN2ADORA3MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | PIM1 4115/4885PRKCQ 3428/4885CYP3A4 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.